"The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis®, Humalog®, Humulin® and Forteo®, as well as continued growth of newer products such as Effient®, Axiron® and Tradjenta®."
this implies that Axiron will be a material contributor to group revenue growth.
pretty awesome to be mentioned in the same sentence as blockbuster names like cymbalta and cialis!
- Forums
- ASX - By Stock
- brief comment from lilly on acr's axiron drug
"The reduction in revenue due to Zyprexa patent expirations is...
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.3¢ |
Change
-0.002(3.08%) |
Mkt cap ! $18.31M |
Open | High | Low | Value | Volume |
6.6¢ | 6.6¢ | 6.3¢ | $5.23K | 80.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 6.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 73455 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 0.063 |
1 | 16145 | 0.062 |
1 | 70000 | 0.061 |
1 | 70000 | 0.060 |
1 | 92500 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 73455 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 15000 | 2 |
0.075 | 149999 | 1 |
Last trade - 15.55pm 05/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |